1. Home
  2. NOMA vs GRDX Comparison

NOMA vs GRDX Comparison

Compare NOMA & GRDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOMADAR Corp.

NOMA

NOMADAR Corp.

N/A

Current Price

$1.16

Market Cap

30.2M

ML Signal

N/A

Logo GridAI Technologies Corp.

GRDX

GridAI Technologies Corp.

N/A

Current Price

$5.34

Market Cap

28.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
NOMA
GRDX
Founded
2023
N/A
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
30.2M
28.6M
IPO Year
2025
2016

Fundamental Metrics

Financial Performance
Metric
NOMA
GRDX
Price
$1.16
$5.34
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
10.9K
★ 101.3K
Earning Date
11-23-2026
11-23-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 21.95
EPS
★ N/A
N/A
Revenue
★ $6,376.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.11
$1.87
52 Week High
$10.00
$6.93

Technical Indicators

Market Signals
Indicator
NOMA
GRDX
Relative Strength Index (RSI) 30.84 58.67
Support Level N/A $2.35
Resistance Level $1.88 $6.00
Average True Range (ATR) 0.18 0.61
MACD -0.05 -0.05
Stochastic Oscillator 7.93 64.66

Price Performance

Historical Comparison
NOMA
GRDX

About NOMA NOMADAR Corp.

Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.

About GRDX GridAI Technologies Corp.

GridAI Technologies Corp, formerly known as Entero Therapeutics Inc, is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.

Share on Social Networks: